The Institute for Clinical and Economic Review (ICER) is seeking nominations of clinicians as well as patient and public representatives to serve on the New England Comparative Effectiveness Public Advisory Council (CEPAC). CEPAC is a regional body that provides objective, independent guidance on the application of medical evidence to clinical practice and payer policy decisions across New England. Supported by a consortium of New England state health policy leaders, provider groups, and payers, CEPAC holds public meetings to consider evidence reviews of medical tests, treatments, and models for health care delivery, and to provide judgments regarding how the evidence can best be used across New England to improve the quality and value of health care services. New council members will be elected to serve for a three-year term, during which they will attend two full-day meetings per year. To nominate, please send a CV and letter of intent to firstname.lastname@example.org. Nomination by sponsoring organizations and self-nominations are both welcome.
For more information, read the full press release here.Read More
CEPAC has released a final evidence report, titled “Controversies in the Management of Patients with Type 2 Diabetes.” The report incorporates findings from a recent public meeting of CEPAC, during which council members reviewed evidence on the effectiveness and value of add-on use of certain medications to improve diabetes control, including sulfonylureas and multiple forms of insulin, as well as two relatively new classes of medications, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. The key findings of the report, along with CEPAC’s votes, suggest that high value treatment options, such as NPH insulin (intermediate-acting human insulin), may be underutilized in many patients. The report also reviews the evidence surrounding the use of insulin pumps and continuous glucose monitors in patients with type 2 diabetes.Read More
The draft report “Controversies in the Management of Patients with Type 2 Diabetes” and related voting questions are now posted for public comment. This report will be the subject of deliberation and vote at the next public meeting of CEPAC on Wednesday, October 29, 2014 in Providence, Rhode Island. This report aims to help members of CEPAC and the public understand the latest evidence on the relative effectiveness and value of various treatment options for individuals with type 2 diabetes, including new classes of oral and injectable medications, insulin, and medical devices. The report includes a systematic review of published literature as well as budget impact analyses. It will be available for public comment until Wednesday, October 22, 2014.